Cheong, J.E. & Sun, L. Targeting the IDO1–TDO2–KYN–AHR pathway for cancer immunotherapy—challenges and opportunities. Trends Pharmacol. Sci. 39, 307–325 (2018).
Prendergast, G.C., Malachowski, W.P., DuHadaway, J.B. & Muller, A.J. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 77, 6795–6811 (2017).
Munn, D.H. & Mellor, A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117, 1147–1154 (2007).
Badawy, A.A.-B., Namboodiri, A.M.A. & Moffett, J.R. The end of the road for the tryptophan depletion concept in pregnancy and infection. Clin. Sci. (Lond.) 130, 1327–1333 (2016).
Sonner, J.K. et al. The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. OncoImmunology 5, e1240858 (2016).
Van de Velde, L.-A. et al. Stress kinase GCN2 controls the proliferative fitness and trafficking of cytotoxic T cells independent of environmental amino acid sensing. Cell Rep. 17, 2247–2258 (2016).
Platten, M., Wick, W. & Van den Eynde, B.J. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res. 72, 5435–5440 (2012).
Puccetti, P. et al. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. PLoS One 10, e0122046 (2015).
Fatokun, A.A., Hunt, N.H. & Ball, H.J. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids 45, 1319–1329 (2013).
Spranger, S. et al. Upregulation of PD-L1, IDO and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).
Mondanelli, G. et al. A Relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity 46, 233–244 (2017).
Holmgaard, R.B., Zamarin, D., Munn, D.H., Wolchok, J.D. & Allison, J.P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA4. J. Exp. Med. 210, 1389–1402 (2013).
Ninomiya, S. et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125, 3905–3916 (2015).
Spranger, S. et al. Mechanism of tumor rejection with doublets of CTLA4, PD-1–PD-L1 or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J. Immunother. Cancer 2, 3 (2014).
Thaker, A.I. et al. IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology 145, 416–425 (2013).
Mezrich, J.D. et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 185, 3190–3198 (2010).
Opitz, C.A. et al. An endogenous tumor-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197–203 (2011).
Seok, S.-H. et al. Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J. Biol. Chem. 293, 1994–2005 (2018).
Theofylaktopoulou, D. et al. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin. Exp. Immunol. 173, 121–130 (2013).
Vécsei, L., Szalárdy, L., Fülöp, F. & Toldi, J. Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 12, 64–82 (2013).
Cervenka, I., Agudelo, L.Z. & Ruas, J.L. Kynurenines: tryptophan's metabolites in exercise, inflammation and mental health. Science 357, eaaf9794 (2017).
Phillips, R.S. Structure and mechanism of kynureninase. Arch. Biochem. Biophys. 544, 69–74 (2014).
Stone, E. et al. Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy. J. Control. Release 158, 171–179 (2012).
Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196, 459–468 (2002).
Hou, D.-Y. et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67, 792–801 (2007).
Banerjee, T. et al. A key in vivo antitumor mechanism of action of natural-product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27, 2851–2857 (2008).
Levina, V., Su, Y. & Gorelik, E. Immunological and non-immunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin. Dev. Immunol. 2012, 173029 (2012).
Pagès, F. et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27, 5944–5951 (2009).
Yuan, J. et al. CTLA4 blockade enhances polyfunctional NY-ESO-1-specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl. Acad. Sci. USA 105, 20410–20415 (2008).
Wainwright, D.A. et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA4 and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20, 5290–5301 (2014).
Holmgaard, R.B., Zamarin, D., Lesokhin, A., Merghoub, T. & Wolchok, J.D. Targeting myeloid-derived suppressor cells with colony stimulating factor–1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase–expressing tumors. EBioMedicine 6, 50–58 (2016).
Grosso, J.F. & Jure-Kunkel, M.N. CTLA4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun. 13, 5 (2013).
Schreiber, T.H., Raez, L., Rosenblatt, J.D. & Podack, E.R. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin. Immunol. 22, 105–112 (2010).
Chung, K.-T. & Gadupudi, G.S. Possible roles of excess tryptophan metabolites in cancer. Environ. Mol. Mutagen. 52, 81–104 (2011).
Moyer, B.J. et al. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor. Toxicol. Appl. Pharmacol. 323, 74–80 (2017).
Terness, P. et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase–expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196, 447–457 (2002).
Sierra, J.R., Cepero, V. & Giordano, S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75 (2010).
Matino, D. et al. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J. Clin. Invest. 125, 3766–3781 (2015).
Koushik, S.V., Sundararaju, B., McGraw, R.A. & Phillips, R.S. Cloning, sequence and expression of kynureninase from Pseudomonas fluorescens. Arch. Biochem. Biophys. 344, 301–308 (1997).
Miroux, B. & Walker, J.E. Overproduction of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 260, 289–298 (1996).